PremiumCompany AnnouncementsShell Advances Regulated Share Buy-Back Programme With New Repurchases20d ago
PremiumTipRanks NewswireNuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset20d agoAZNNVS
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
PremiumCompany AnnouncementsBarclays Strengthens Board Nominations Committees With New Appointment21d ago